title: Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice.
abstract: OBJECTIVE
  This study aimed at determining whether oral administration of a probiotic strain, Lactobacillus casei strain Shirota (LcS), can improve insulin resistance, which is the underlying cause of obesity-associated metabolic abnormalities, in diet-induced obesity (DIO) mice.
  
  
  RESULTS
  DIO mice were fed a high-fat diet without or with 0·05% LcS for 4 weeks and then subjected to an insulin tolerance test (ITT) or oral glucose tolerance test (OGTT). Oral administration of LcS not only accelerated the reduction in plasma glucose levels during the ITT, but also reduced the elevation of plasma glucose levels during the OGTT. In addition, plasma levels of lipopolysaccharide-binding protein (LBP), which is a marker of endotoxaemia, were augmented in the murine models of obese DIO, ob/ob, db/db and KK-A(y) and compared to those of lean mice. LcS treatment suppressed the elevation of plasma LBP levels in DIO mice, but did not affect intra-abdominal fat weight.
  
  
  CONCLUSIONS
  LcS improves insulin resistance and glucose intolerance in DIO mice. The reduction in endotoxaemia, but not intra-abdominal fat, may contribute to the beneficial effects of LcS.
  
  
  CONCLUSIONS
  This study suggests that LcS has the potential to prevent obesity-associated metabolic abnormalities by improving insulin resistance.
authors.affiliation: Yakult Central Institute for Microbiological Research, Kunitachi-shi, Tokyo, Japan.
authors.forename: E
authors.initials: E
authors.lastname: Naito
authors.forename: Y
authors.initials: Y
authors.lastname: Yoshida
authors.forename: K
authors.initials: K
authors.lastname: Makino
authors.forename: Y
authors.initials: Y
authors.lastname: Kounoshi
authors.forename: S
authors.initials: S
authors.lastname: Kunihiro
authors.forename: R
authors.initials: R
authors.lastname: Takahashi
authors.forename: T
authors.initials: T
authors.lastname: Matsuzaki
authors.forename: K
authors.initials: K
authors.lastname: Miyazaki
authors.forename: F
authors.initials: F
authors.lastname: Ishikawa
mesh_terms: D000209:Acute-Phase Proteins; D000284:Administration, Oral; D000818:Animals; D001835:Body Weight; D002352:Carrier Proteins / Q000097:blood; D059305:Diet, High-Fat; D004195:Disease Models, Animal; D018149:Glucose Intolerance / Q000628:therapy; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance / Q000502:physiology*; D050152:Intra-Abdominal Fat / Q000378:metabolism; D007780:Lacticaseibacillus casei / Q000502:physiology*; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood; D051379:Mice; D008810:Mice, Inbred C57BL; D008820:Mice, Obese; D009765:Obesity / Q000097:blood / Q000382:microbiology* / Q000628:therapy*; D019936:Probiotics / Q000627:therapeutic use*; D000099231:Lipopolysaccharide-Binding Protein
chemical_list: D000209:Acute-Phase Proteins; D002352:Carrier Proteins; D007328:Insulin; D008562:Membrane Glycoproteins; D000099231:Lipopolysaccharide-Binding Protein